CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.
Listed are current opportunities for patient groups, clinician groups, drug plans, and cancer agencies to provide input or feedback on drugs being assessed within the Drug Reimbursement Review process.
At CADTH, input is information, insight, or advice given to CADTH to contribute to a review. Feedback is a response to a prepared proposal, review report, or draft recommendation.
Indications: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus: as monotherapy when metformin is considered inappropriate due to intolerance or contraindications; in combination with other medicinal products for the treatment of diabetes
Indications: Indicated in adults and adolescents 12 years and older as an add-on maintenance treatment for moderate-to-severe asthma characterized by type 2 inflammation. Indicated as maintenance therapy to improve lung function. Indicated as maintenance therapy for oral corticosteroid-dependent asthma irrespective of type 2 inflammatory markers.